A controlled trial of methylene blue in severe depressive illness

Biological Psychiatry

Volumn 22, Issue 5, 1987, Pages 657-659

  Naylor, G J ^a   Smith, A H W ^b   Connelly, P ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b Royal Dundee Liff Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; METHYLENE BLUE; PLACEBO;

CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG THERAPY; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; THERAPY;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMAN; METHYLENE BLUE; MIDDLE AGE;

EID: 0023272154     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-3223(87)90194-6     Document Type: Article

References (8)

1. An inventory for measuring depression
2. Diagnostic criteria for use in psychiatric research
3. Development of a rating scale for primary depressive illness
4. A new depression scale designed to be sensitive to change
5. Vanadium and affective disorders
6. Possible explanation for therapeutic action of lithium and a possible substitute (methylene blue)
7. Catalysis of the reduction of vanadate by psychotropic drugs
8. A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis